BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US: AN UPDATED ANALYSIS
    Campbell, D.
    Veenstra, D.
    Migliaccio-Walle, K.
    Dzingina, M.
    Sullivan, S.
    Draica, F.
    Wiemken, T.
    Cha-Silva, A.
    Mugwagwa, T.
    VALUE IN HEALTH, 2024, 27 (06) : S119 - S119
  • [2] Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
    Sandin, Rickard
    Veenstra, David L.
    Vankelegom, Mathilde
    Dzingina, Mendwas
    Sullivan, Sean D.
    Campbell, David
    Ma, Cuiying
    Harrison, Cale
    Draica, Florin
    Wiemken, Timothy Lee
    Mugwagwa, Tendai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (12): : 1290 - 1302
  • [3] Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
    Carlson, Josh
    Foos, Volker
    Kasle, Adam
    Mugwagwa, Tendai
    Draica, Florin
    Wiemken, Timothy Lee
    Nguyen, Jennifer L.
    Cha-Silva, Ashley
    Migliaccio-Walle, Kristen
    Dzingina, Mendy
    VALUE IN HEALTH, 2024, 27 (02) : 164 - 172
  • [4] Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
    Duarte, Carlos H. Arteaga
    Peters, Michel L.
    de Goeij, Michelle H. M.
    Spijkerman, Roy
    Postma, Maarten J.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2025, 23 (01):
  • [5] COST-EFFECTIVENESS ANALYSIS OF NIRMATRELVIR/RITONAVIR COMPARED WITH MOLNUPIRAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN JAPAN
    Yuasa, A.
    Matsuda, H.
    Fujii, Y.
    Kado, Y.
    Murata, K.
    Yoshida, M.
    Mugwagwa, T.
    Gu, Y.
    VALUE IN HEALTH, 2024, 27 (12) : S89 - S89
  • [6] COST-EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS AT HIGH-RISK FOR PROGRESSION IN SPAIN
    Peral, C.
    Azanza, J. R.
    Gonzalez del Castillo, J. M.
    Ferrando, R.
    Molero Garcia, J. M.
    Soriano, A.
    Ariznavarreta Martin, A.
    Gari, C.
    De Lossada Juste, A.
    Lopez Gomez, V
    VALUE IN HEALTH, 2024, 27 (12) : S129 - S129
  • [7] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [8] Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain
    Azanza, Jose Ramon
    Gonzalez Del Castillo, Juan Maria
    Ferrando, Raul
    Molero, Jose Maria
    Soriano, Alex
    Peral, Carmen
    de Lossada, Alfonso
    Bellmunt, Alba
    Gari, Carla
    Mugwagwa, Tendai
    Lopez-Gomez, Vanessa
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
  • [9] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
    Lu, Jiayue
    Cai, Hong
    Hao, Yujun
    Lin, Zhang
    Liu, Shang
    Zhan, Yaping
    Ding, Li
    Huang, Meilan
    Li, Zhenyuan
    Xu, Lan
    Yan, Xiujuan
    Yang, Li
    Zhang, He
    Zhang, Wei
    Zhao, Li
    Zhao, Junli
    Wang, Ting
    Gu, Leyi
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] In patients with COVID-19 at risk for severe disease, nirmatrelvir plus ritonavir reduced hospitalization or death
    Vassilopoulos, Athanasios
    Mylonakis, Eleftherios
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (06) : JC63 - JC63
12345